.jpg)
BIOMARKERS AND METHOD FOR PREDICTING OR FORECASTING RESPONSE TO TREATMENT WITH BRAF AND MEK INHIBITORS (BRAFi + MEKi) IN PATIENTS WITH METASTATIC MELANOMA
The treatment of melanoma today has allowed the development of cancer immunology. Currently, immunotherapy for metastatic melanoma is based on immune checkpoint inhibitors (ICIs). Immunotherapy has meant the longest survival for melanoma patients. At the same time, a therapy targeting specific mutations has been developed, specifically BRAF (BRAF and MEK inhibitors, BRAFi + MEKi), which produce large tumor regression responses, as well as a percentage of long survivors. Targeted therapy against BRAF is the standard treatment for metastatic melanoma with this mutation. Blocking this gene is known to alter cancer immunology. Currently the criteria to be considered for line change are based on radiological tests. Therefore, it is considered necessary to identify response biomarkers that predict whether the treatments are adequate, advancing clinical decisions and, therefore, avoiding the unnecessary exposure of treatments that are not working in the patient. The object of this invention is the development of biomarkers and a method for predicting or prognosticate the response to cancer treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for monitoring patients.
The treatment of melanoma today has allowed the development of cancer immunology. Currently, immunotherapy for metastatic melanoma is based on immune checkpoint inhibitors (ICIs). Immunotherapy has meant the longest survival for melanoma patients. At the same time, a therapy targeting specific mutations has been developed, specifically BRAF (BRAF and MEK inhibitors, BRAFi + MEKi), which produce large tumor regression responses, as well as a percentage of long survivors. Targeted therapy against BRAF is the standard treatment for metastatic melanoma with this mutation. Blocking this gene is known to alter cancer immunology. Currently the criteria to be considered for line change are based on radiological tests. Therefore, it is considered necessary to identify response biomarkers that predict whether the treatments are adequate, advancing clinical decisions and, therefore, avoiding the unnecessary exposure of treatments that are not working in the patient. The object of this invention is the development of biomarkers and a method for predicting or prognosticate the response to cancer treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for monitoring patients. The treatment of melanoma today has allowed the development of cancer immunology. Currently, immunotherapy for metastatic melanoma is based on immune checkpoint inhibitors (ICIs). Immunotherapy has meant the longest survival for melanoma patients. At the same time, a therapy targeting specific mutations has been developed, specifically BRAF (BRAF and MEK inhibitors, BRAFi + MEKi), which produce large tumor regression responses, as well as a percentage of long survivors. Targeted therapy against BRAF is the standard treatment for metastatic melanoma with this mutation. Blocking this gene is known to alter cancer immunology. Currently the criteria to be considered for line change are based on radiological tests. Therefore, it is considered necessary to identify response biomarkers that predict whether the treatments are adequate, advancing clinical decisions and, therefore, avoiding the unnecessary exposure of treatments that are not working in the patient. The object of this invention is the development of biomarkers and a method for predicting or prognosticate the response to cancer treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for monitoring patients.